Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Art of Investing -- Ignore unavailable to you. Want to Upgrade?

To: Sun Tzu who wrote (10725)	1/18/2026 8:44:33 PM
From: Arran Yuan	Read Replies (2) \| Respond to of 10768

Biopharmaceutical companies are generally a kind that is very hard to seriously invest in from my biological perspective. A good kind to speculate, though. Biomedical research is so into molecular, and lacks of consideration for how that molecular interacts with targets, let alone the impact of such reaction on other related events, which is often a sequential of multiple steps process. Thus, small biomedceuticals are much better approached by your proprietary 3-day data points charting o-:) As a side note, such small companies could have rarely marketed their products due to the market characteristics of medicine, even if their RnD succeed. Therefore, the most optimistic outcome is often that they are bought out by the biggies. BTW, would really appreciate if you, or anyone on SI, could give me a charting of the Shanghai Stock Exchange ($SSEC).